Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of GLS-5310 DNA Vaccine Against SARS-CoV-2
NCT05085639Phase 1Unknown
- Sponsor
- GeneOne Life Science, Inc.
- Start
- Nov 2021
- Primary completion
- Apr 2022
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of GLS-5310 in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by GeneOne Life Science, Inc. Primary endpoints: Incidence of adverse events at 56 weeks and Geometric mean titer (GMT) of antigen specific antibody titers at 56 weeks. Status: unknown.
02
Drugs
GLS-5310
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05085639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05085639.